No announcement yet.

7 drugs making waves in the spine field

  • Filter
  • Time
  • Show
Clear All
new posts

    7 drugs making waves in the spine field

    7 drugs making waves in the spine field
    "Some people say that, the longer you go the better it gets the more you get used to it, I'm actually finding the opposite is true."

    -Christopher Reeve on his Paralysis


    7 drugs making waves in the spine field

    Alan Condon - Tuesday, September 29th, 2020 Print | Email

    A variety of drugs and drug-biologics have been making headlines in the spine field in the past year. Here are seven products that have received regulatory approval or are undergoing clinical trials for the treatment of spinal conditions:

    1. In September, biopharmaceutical company AbbVie received Fast Track designation for elezanumab, a drug for the treatment of patients with spinal cord injury. Elezanumab, a monoclonal antibody, intends to block a molecule that can hinder neuronal regeneration and functional recovery after central nervous system damage.

    2. In August, the FDA approved the third drug for the treatment of neuromyelitis optica spectrum disorder, which affects the optic nerves and spinal cord. Enspryng, developed by Genentech, was shown to be a safe and effective treatment for NMOSD in clinical trials.

    3. Genentech also received FDA clearance for Evrysdi, a drug for spinal muscular atrophy in adults and children 2 months of age and older. Genentech is the third company to receive approval for an SMA drug. Evrysdi has a market price of $340,000 annually and is based on the weight of the patient.

    4. In May, the European Commission approved Zolgensma, Novartis' $2.1 million gene therapy drug for SMA, for infants and children up to 46 pounds. Priced at $2.1 million, Zolgensma has been dubbed "the world's most expensive drug" and was cleared by the FDA in June 2019.

    5. Orthobiologics company Kuros Biosciences is evaluating Fibrin-PTH for transforaminal...

    Last edited by Oddity; 13 Oct 2020, 10:34 PM. Reason: Edited down from whole recreation of source article for copyright purposes
    C-5, 6 SCI. Took about 6 months to walk. Walking full time. Without any assistance since Nov. 2003 and will make a full recovery


      I've noticed that elezanumab is in the last months of phase 2 trial for MS. Can it be much longer til it's approved for SCI or could it be used off-label? -Jan
      Last edited by FellowHawkeye; 20 Oct 2020, 8:52 PM.


        Just looking at Abbvie's Elezanumab... It looks like they are testing on acute SCI only.... Does anyone know if Abbvie think this application will benefit chronics at some point?